Dr. Daniel Kim is a board-certified geriatric psychiatrist who serves as medical director of the inpatient geriatric psychiatry service and program director of the geriatric psychiatry fellowship. His primary area of interest is in the education of medical students, residents, and fellows in geriatric psychiatry.

Academic Appointments

  • Clinical Associate Professor, Psychiatry and Behavioral Sciences

Administrative Appointments

  • Program Director, Geriatric Psychiatry Fellowship, Stanford University School of Medicine (2022 - Present)
  • Medical Director, Inpatient Geriatric Psychiatry Service Stanford Hospital (2016 - Present)
  • Associate Medical Director, Senior Behavioral Health Inpatient Unit University of California San Diego Medical Center (2008 - 2016)

Professional Education

  • Clinical Fellowship, University of California, San Diego, Geriatric Psychiatry (2005)
  • Residency, University of Illinois, Chicago, General Psychiatry (2004)
  • M.D., Loma Linda University School of Medicine, Medicine (2000)

Graduate and Fellowship Programs

  • Geriatric Psychiatry (Fellowship Program)

All Publications

  • A Randomized Controlled Trial of Atomoxetine in Generalized Social Anxiety Disorder JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY Ravindran, L. N., Kim, D. S., Letamendi, A. M., Stein, M. B. 2009; 29 (6): 561-564


    The current mainstays of social anxiety disorder pharmacotherapy are serotonergic agents, with less known about the efficacy of more noradrenergic drugs. Atomoxetine (ATM), a highly selective norepinephrine reuptake inhibitor, is currently approved for the treatment of attention-deficit/hyperactivity disorder (ADHD). We describe the first controlled trial of ATM with respect to efficacy and tolerability in adults with the generalized subtype of social anxiety disorder (GSAD) without comorbid ADHD. Twenty-seven outpatients with clinically prevailing diagnoses of GSAD by the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition were randomized in a 1:1 ratio to 10 weeks of double-blind flexible-dose treatment with either ATM 40-100 mg per day (n = 14) or placebo (n = 13). Primary efficacy outcome was score at end point on the Liebowitz Social Anxiety Scale in the intention-to-treat sample. There were no significant group differences in patients completing the study (ATM, 79%; placebo, 77%). Whereas ATM was well tolerated, there were no significant differences in clinical efficacy between ATM and placebo for GSAD. There were few responders overall (ATM, 21%; placebo, 33%), but proportions were similar in each group (chi [1, 26] = 0.47; P = 0.67). Analysis of variance with repeated measures on the Liebowitz Social Anxiety Scale was performed to detect any differential change in social anxiety symptoms between groups. A significant time effect was found (F = 8.71; P = 0.007), but the time-by-treatment interaction was nonsignificant (F = 0.013; P = 0.91). Although the small sample size limits confidence in the reported results, the comparable, and low, response rates for ATM and placebo suggest that in the absence of comorbid ADHD, ATM is unlikely to be an effective agent for the treatment of GSAD.

    View details for DOI 10.1097/JCP.0b013e3181bf6303

    View details for Web of Science ID 000272004300008

    View details for PubMedID 19910721

  • Worth the Risk? Relationship of Incentives to Risk and Benefit Perceptions and Willingness to Participate in Schizophrenia Research SCHIZOPHRENIA BULLETIN Dunn, L. B., Kim, D. S., Fellows, I. E., Palmer, B. W. 2009; 35 (4): 730-737


    Providing incentives for research participation is widely practiced but minimally studied. In schizophrenia research, questions about capacity to consent and potential vulnerability may raise concerns when offering incentives for participation. Despite empirical attention focused on consent and decision-making capacity in schizophrenia, the issue of incentives has been essentially ignored. We examined willingness to participate in research, in relation to perceived risks and benefits, among people with schizophrenia and schizoaffective disorder.Forty-six people with schizophrenia or schizoaffective disorder rated perceived risks and benefits of 5 hypothetical research vignettes. They also indicated whether they would be willing to participate at each of 5 incentive levels (including no compensation). Cognition was assessed with Mattis Dementia Rating Scale.Ratings of risk and potential personal benefit were inversely correlated. For all scenarios, significant correlations were found between perceived risk and willingness to participate for greater compensation. Conversely, lower perceived likelihood of benefit was associated with a higher compensation threshold for participation in each scenario. Even at the highest proffered payment level for each scenario, however, a substantial proportion of respondents were not willing to participate. Risk assessment and willingness to participate (at all levels of compensation) were not associated with demographic variables or cognitive status.Determining whether incentives impede voluntarism remains an important task for empirical ethics research. Assessing potential research participants' understanding and perceptions of risks, benefits, and alternatives to participation will help ensure that informed consent fulfills its mission--embodying the ethical principle of respect for persons.

    View details for DOI 10.1093/schbul/sbn003

    View details for Web of Science ID 000268241700012

    View details for PubMedID 18281293

    View details for PubMedCentralID PMC2696364

  • Chronic pain and depression among geriatric psychiatry inpatients INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY Meeks, T. W., Dunn, L. B., Kim, D. S., Golshan, S., Sewell, D. D., Atkinson, J. H., Lebowitz, B. D. 2008; 23 (6): 637-642


    We examined whether chronic pain among depressed geriatric inpatients was associated with several clinical variables-comorbid psychiatric and medical diagnoses, length of hospitalization, suicidal ideation, and sleep duration.Medical charts of inpatients admitted to a geriatric psychiatry unit over 2 years were examined retrospectively; 148 patients with a depressive disorder were identified. Admission pain assessments were used to classify whether patients had chronic pain. Other variables of interest were collected from charts.62% of patients reported chronic pain. In multivariate regression analysis, depressed older adults with chronic pain were more likely to report suicidal ideation, be diagnosed with personality disorder, have higher medical burden, and experience decreased total sleep time compared to depressed older adults without chronic pain.Chronic pain--common in depressed older adults--may influence clinical features of depression and should be assessed as a possible suicide risk factor. Prospective studies should examine causal relationships and determine the effects of adequate pain treatment on depression course and suicide risk in older adults.

    View details for DOI 10.1002/gps.1954

    View details for Web of Science ID 000256859100013

    View details for PubMedID 18041102

  • Anxiety disorders in a public mental health system: Clinical characteristics and service use patterns JOURNAL OF AFFECTIVE DISORDERS Wetherell, J. L., Kim, D. S., Lindamer, L. A., Thorp, S. R., Hawthorne, W., Kim, K., Hough, R. L., Garcia, P., Jeste, D. V. 2007; 104 (1-3): 179-183


    Anxiety disorders are among the most common forms of psychiatric disorder, yet few investigations have examined the prevalence or service use of clients with anxiety disorders in the public mental health sector.We examined demographics, clinical information, and service use in clients with anxiety disorders enrolled in San Diego County Adult and Older Adult Mental Health Services in fiscal 2002-2003.Almost 15% of the sample had a diagnosis of an anxiety disorder based on administrative billing data. Most anxiety disorder clients had additional psychiatric diagnoses, most commonly depression. Clients with both anxiety disorders and depression were more likely than those with anxiety or depression alone to use emergency psychiatric services and outpatient services than those with depression alone. Those with anxiety disorders alone used more outpatient services than those with depression alone.Data were taken from an administrative database.Data indicate that anxiety disorders are not uncommon in public mental health settings and are associated with higher utilization of outpatient mental health services.

    View details for DOI 10.1016/j.jad.2007.02.021

    View details for Web of Science ID 000251489600022

    View details for PubMedID 17408752

  • Research agenda for DSM-V: Diagnostic categories and criteria for neuropsychiatric syndromes in dementia JOURNAL OF GERIATRIC PSYCHIATRY AND NEUROLOGY Jeste, D. V., Meeks, T. W., Kim, D. S., Zubenko, G. S. 2006; 19 (3): 160-171


    Neuropsychiatric symptoms in dementia represent a major health burden for older adults. These symptoms are often more distressing, impairing, and costly than cognitive symptoms in dementia, yet they have been less coherently categorized in the various versions of the Diagnostic and Statistical Manual of Mental Disorders (DSM). The preponderance of literature on psychiatric symptoms in dementia has been in patients with Alzheimer's disease. Diagnostic criteria have been proposed for psychosis, depression, and sleep disturbance in Alzheimer's disease. "Agitation" also appears to be a clinically important behavioral complication of dementia that warrants further study. Beginning with further validation of these proposed diagnostic criteria, future research can guide a more clinically meaningful description of these syndromes in DSM-V. Advancing biotechnology offers promise for discoveries related to the etiology and treatment of these syndromes. New research in this field should encompass diverse populations and different types of dementia. The high emotional and economic costs of neuropsychiatric symptoms in dementia implore diagnostic refinement to facilitate improved treatment.

    View details for DOI 10.1177/0891988706291087

    View details for Web of Science ID 000240020900007

    View details for PubMedID 16880358